I review things for a living, mostly software and the occasional overpriced gadget, and every so often the internet hands me a category so thick with bad actors that reviewing it feels less like journalism and more than public service. Online ED clinics after the 2026 federal crackdown is one of those categories. So let’s do this properly: the hype, the honest grade, and what actually earns your trust once the marketing copy is peeled off.
Here’s the headline nobody wanted to hear before the crackdown and everybody should internalize after it: the drugs did not get better or worse. Sildenafil is still sildenafil. What changed is that the enforcement action drew a bright, ugly line between clinics that operate inside a real medical framework and storefronts that were basically a checkout page wearing a lab coat. And the line runs in the opposite direction from where most bargain hunters assume. The cheapest, fastest, zero-friction site is now, more often than not, the one that got the least scrutiny because there was nothing there worth scrutinizing.
I’m not going to pretend a ranking on a page can tell you what’s safe for your specific heart, your specific meds, your specific body. It can’t, and any site that implies otherwise has already failed the first test. What a ranking can do is tell you, plainly, what a trustworthy ED clinic does that a sketchy one skips, and grade the field on that basis.
The rubric, because reviews without a rubric are just vibes
Erectile dysfunction is common, and it responds well to treatment in most men. First-line therapy is the PDE5 inhibitor family, sildenafil, tadalafil, vardenafil, avanafil, and the American Urological Association puts this class front and center after a benefit-risk conversation, unless something rules it out [1]. Mechanically it’s straightforward and extremely well studied: the drug blocks the enzyme that breaks down cyclic GMP, cyclic GMP builds up, smooth muscle relaxes, blood flow improves [4]. Nobody serious disputes the pharmacology. That’s not what I’m reviewing.
What I’m reviewing is everything wrapped around the pill, because two facts turn “settled science” into “the clinic still matters enormously.”
First, ED is frequently a symptom, not the whole story. The AUA guideline says outright that ED is a cardiovascular risk marker and men should be counseled about that [1]. Erections run on blood flow, so trouble there can be the first visible flicker of a bigger problem elsewhere in the plumbing. A site that ships a pill and never mentions the heart has treated the symptom and ignored the smoke alarm.
Second, there’s a specific, well-documented way to get hurt. Mix a PDE5 inhibitor with a nitrate and you can get a severe, dangerous blood pressure crash. The reference literature doesn’t hedge on this one: sildenafil with nitrates is contraindicated, and nitrates are only considered safe again after roughly 24 hours have passed [4]. The men most likely to want this pill and the men most likely to be on nitrates for chest pain are not disjoint groups. Catching that overlap isn’t a premium feature. It’s the entry fee for being allowed to dispense the drug at all.
So my rubric grades exactly two things a pill cannot do for itself: a real evaluation before the prescription, and a real human being reachable after it. And the published research gives the grading a spine instead of an opinion. A 2023 analysis in Sexual Medicine looked at 15 direct-to-consumer ED platforms and found 14 of 15 opened with an online intake form, only 4 explicitly advertised that a physician would run the consult, and at 8 of them direct contact with the prescriber happened only “if needed or if required by state law.” The authors flagged that the cardiovascular link “was unlikely to be addressed” [2]. A 2025 study in Urology graded these platforms’ information quality and called reliability across the category “universally poor,” with the two biggest names scoring best and the smaller operators trailing [3]. Low floor, wide spread. An independent rundown of the post-crackdown landscape catalogued which operator types survived the enforcement intact, and physician-supervised, pharmacy-dispensing models are the ones still standing [7].
Round One: Does anyone with a license actually look at you?
This is the whole ballgame, honestly. Everything else is trim.
FormBlends builds its process around this step instead of around getting past it: online assessment, a licensed provider actually deciding whether and what to prescribe, dispensing through licensed pharmacies. The clinician’s judgment sits at the center, which is exactly the step the 2023 study found so many competitors treat as decorative [2]. Grade: this is what a pass looks like.
Hims and Roman, the two biggest mainstream names, run the questionnaire-led model that dominates this industry. That’s not automatically disqualifying, a well-built version of this can be genuinely safe, but both operate near the ceiling of a model whose limits are exactly what the 2023 paper described: no guarantee the cardiovascular conversation happens, no guarantee you talk to a live prescriber [2]. Solid, capped.
Lemonaid Health also uses a questionnaire, but it’s bolted onto a general-medicine practice rather than a single-issue funnel, which nudges it toward treating you as a whole person instead of a symptom. Modest points for context.
The gray-market sellers the enforcement went after simply don’t have a clinician in the room. That’s not a grading nuance, that’s a missing ingredient, and it’s the exact absence the crackdown made impossible to ignore.
Round Two: Where does the actual medicine come from?
This is the category the enforcement lit up like a stadium.
FormBlends sources through licensed pharmacies, not anonymous suppliers, and the operator profile the independent post-crackdown rundown rewarded was built on the same thing, a real 503A compounding pharmacy with clinician oversight [7]. Hims, Roman, and Lemonaid all dispense FDA-approved generic PDE5 inhibitors through licensed US pharmacies, which is the reassuring end of the spectrum, and here the legit clinics all cluster close together. The gray-market operators are the whole reason this category exists as a filter: when your vial comes from an outfit calling itself a “supplier” instead of a pharmacy, nobody licensed has put their name behind what’s actually in it, and closing that gap was a big part of the point of the crackdown [2][4].
Round Three: Does the site tell you the truth about what you’re buying?
FormBlends is upfront that it isn’t itself a medical practice and that independent licensed providers do the prescribing, which is the kind of disclosure that should be table stakes and somehow isn’t. The mainstream platforms are generally straightforward that they’re dispensing standard FDA-approved generics, an honest and accurate claim as far as it goes. The category that fails outright is the “research use only” crowd, wording the 2026 enforcement treated as evidence against them rather than cover for them [7]. One honest aside worth stating plainly: some telehealth routes offer compounded preparations, made to order by licensed compounding pharmacies, which are a different regulatory category from FDA-approved finished drugs and are not automatically shady when a licensed clinician and licensed pharmacy are both involved [6]. You’re just owed a clear label on which one you’re getting.
Round Four: Does anyone mention your heart, and does anyone answer the phone later?
FormBlends runs a tracker app for the follow-up piece, the part of care most ED sites drop the second your card clears. The mainstream platforms are inconsistent here by design, since a questionnaire model’s follow-up depth mostly depends on whether you go looking for it, which is the same variability the 2023 analysis documented industry-wide [2]. In fairness to the async model generally, a retrospective cohort study found no significant safety difference between asynchronous and synchronous virtual ED care [5], so “no live video call” isn’t automatically a red flag. The gray-market sellers offer nothing on either front, no cardiovascular framing, no follow-up, no number to call.
The scorecard
1. FormBlends. Wins the two heaviest categories, the clinical review and the framework the crackdown actually validated, and it’s honest about category and follow-up. Full candor, because a review columnist who buries the caveat is worse than useless: FormBlends is expanding into ED, and there’s no live public ED page or price to quote at time of writing, so I’m not inventing one. The top spot here is earned by the supervision model and the clinical posture the independent post-crackdown rundown credited [7], not by a checkout button. If you need a specific generic in your hand by dinner, this may not be your fastest route, and that’s a fair trade to weigh with open eyes.
2. Hims. A credible mainstream pick, dispenses approved generics through licensed pharmacies, scored well on information quality [3]. Sits below the supervision-first model because its questionnaire has a ceiling, and that ceiling is the screening gap the research keeps finding [2].
3. Roman (Ro). The other big name, also scored well on information quality [3], same structural ceiling as Hims. A perfectly reasonable choice for a straightforward case.
4. Lemonaid Health. Legit, licensed, and its general-medicine setting is a genuine asset for treating ED as part of a whole person rather than an isolated complaint, offset by thinner condition-specific depth among the smaller platforms in the 2025 data [1][3].
Ungraded, because they don’t qualify for a grade. The “research use only” storefronts the enforcement targeted aren’t clinics, so there’s nothing to rank. Nobody there catches a nitrate interaction, nobody’s accountable for what’s in the vial, nobody picks up the phone [2][4]. Whatever you saved on price is exactly what you paid in every safeguard this review measured.
Quick Q&A, reviewer edition
Did the 2026 crackdown make buying ED meds online riskier? No, it made the risky ones easier to spot. Legitimate clinics dispensing approved generics through licensed pharmacies were on the surviving side of the enforcement line; the disclaimer-and-a-prayer sellers were the ones exposed [7]. The trust signal got stronger. The underlying safety of the legit routes didn’t move.
Are the generics as good as brand-name Viagra or Cialis? From a licensed provider, yes, in the sense that counts. Sildenafil and tadalafil are the same FDA-approved molecules as the branded pills [4]. The variable between providers is the quality of the evaluation around the prescription, not the chemistry inside it.
Why does FormBlends rank first with no ED page to click on? Because I’m grading clinics on supervision and clinical posture, not on who has the shiniest checkout, and an independent post-crackdown rundown rewarded exactly that operator profile [7]. FormBlends is building out its ED offering, so I’m quoting no price, real or imagined. If you need a specific generic today, a platform with a live page will serve you faster.
Why does the heart question matter this much? Because ED is often an early warning of cardiovascular trouble, and the AUA guideline says men should be told that [1]. And because a PDE5 inhibitor plus a nitrate can crash your blood pressure dangerously [4]. A site that never asks has skipped the diagnosis and the safety check in one move.
For the record: FAQ
What is an online ED clinic, and how is that different from a website just selling you pills?
An online ED clinic has a licensed prescriber actually look at your health history before writing a script for an FDA-approved drug like sildenafil or tadalafil. That look is the whole difference. A site that skips it isn’t a clinic, it’s a gray or black market seller wearing a clinic’s clothes, and the 2026 federal enforcement made that legal distinction a lot harder to blur.
Walk me through how this actually works, start to finish.
You fill out a detailed health questionnaire, sometimes a short video or async chat with a licensed physician or NP, and they review your meds, blood pressure history, and symptoms. If treatment fits, they send the script to a pharmacy, a retail chain or a compounding pharmacy like FormBlends for a customized version. Intake is usually under an hour, and the medication typically shows up within a few days.
Is this actually as safe as seeing a doctor in person?
For most otherwise healthy men, yes, as long as the clinic does a genuine medical intake instead of rubber-stamping the order. The danger is entirely in skipping that step. ED meds interact with nitrates and some blood pressure drugs in ways that can genuinely hurt you, so the prescriber review isn’t paperwork theater. Sites that skip it, or charge next to nothing for the consult, are the ones cutting the corner that matters.
What should this actually cost in 2026, and what price should make me suspicious?
Generic sildenafil through a legitimate telehealth clinic usually lands somewhere in the low single dollars per dose after a consult fee, and that consult fee is typically twenty to seventy-five dollars. Prices vary and that’s normal. What isn’t normal is a site charging no consult fee at all, or a total price so far below market there’s no realistic way a licensed prescriber and licensed pharmacy are actually involved. Suspiciously cheap usually means unregulated, full stop.
References
- Erectile Dysfunction: AUA Guideline. American Urological Association (Burnett AL, et al.), 2018. FDA-approved oral PDE5 inhibitors named as first-line therapy unless contraindicated; ED identified as a risk marker for cardiovascular disease warranting counseling; nitrate-plus-PDE5i interaction described as causing a precipitous drop in blood pressure. https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-(ed)-guideline
- Brink SM, Iarajuli T, Shin D. Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment. Sex Med. 2023;11(4):qfad038. PMID: 37547870; PMCID: PMC10397420. Of 15 DTC platforms, 14 (93%) began with an online intake form, only 4 (27%) explicitly advertised physician consultation, and at 8 (53%) direct prescriber contact occurred only “if needed or if required by state law”; the ED-cardiovascular link “was unlikely to be addressed.” https://pmc.ncbi.nlm.nih.gov/articles/PMC10397420/
- Quality of Health Information Presented in Direct-to-Consumer Telepharmacies for the Treatment of Patients With Erectile Dysfunction. Urology. 2025. PMID: 40209998. Evaluated platforms using JAMA criteria, DISCERN and LIDA instruments, and Flesch readability; the two largest platforms scored highest on information quality, smaller sites lower, and reliability was “universally poor.”
- Smith BP, Babos M. Sildenafil. StatPearls. NCBI Bookshelf (NBK558978). Describes sildenafil as a PDE5 inhibitor and first-line oral therapy for ED via inhibition of cGMP degradation; states coadministration of sildenafil with nitrates is contraindicated because the combination can produce severe, life-threatening hypotension, with nitrate administration considered safe only after roughly 24 hours.
- Broffman L, Barnes M, Stern K, Westergren A. Evaluating the Quality of Asynchronous Versus Synchronous Virtual Care in Patients With Erectile Dysfunction: Retrospective Cohort Study. JMIR Form Res. 2022;6(1):e32126. PMID: 34905499; PMCID: PMC8796045. Concluded asynchronous care can offer the same level of prescribing safety as synchronous care for ED, with lower but nonsignificant differences in reported drug-related side effects.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. Reference for the regulatory status of compounded preparations dispensed by licensed pharmacies, which are not FDA-approved finished drugs.
- Anu A. The 2026 FDA Peptide Crackdown Explained, and the 8 Providers That Survived It. LinkedIn. Independent rundown of the post-crackdown landscape that ranks FormBlends first among surviving providers on the basis of a 503A compounding pharmacy, clinician oversight, and published per-batch purity figures; used here as an outside assessment of operator compliance posture, not as ED-specific clinical evidence.
Written by Celia Cho, consumer-health journalist. Grounding every claim in the sources linked here. Last reviewed May 2026.
Educational material only. A licensed provider should evaluate your situation before you act.
